Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis

Abstract

For physicians who care for patients with multiple sclerosis (MS), the use of disease-modifying therapies (DMTs) during the conception period and pregnancy raises important safety considerations. All DMTs have potential adverse effects on fertility, pregnancy outcomes, and breastfed infants. Although physicians are reluctant to prescribe DMTs to MS patients who are contemplating having a family or are already pregnant, treatment can be warranted in those who have active disease. This review assembles the most current information on the reproductive safety of approved and emerging DMTs drawn from the literature and information supplied by the manufacturers.